Verified· 3 sources

Asceneuron SA

Summary

About the company

The core activity of Asceneuron SA is the development of innovative small molecules and Tau modifiers for the treatment of diseases, particularly in the area of the central nervous system (CNS). The company focuses on the early stages of drug development and conducts clinical trials to test the efficacy and safety of its active ingredients.

AI-generated

Offering

Products & services

Industry:Pharmaceutical Industry

✓ Offered4

Development of oral therapeutics for neurodegenerative diseases

Development of oral therapeutics targeting the causes of neurodegenerative diseases, with a portfolio of small molecules in clinical development.

Development of O-GlcNAcase inhibitors (OGA)

Small-molecule O-GlcNAcase inhibitors, including ASN51 and ASN90, developed to slow protein aggregation and treat pathological proteins.

Development of treatments for Alzheimer's disease

Development of therapeutic candidates for Alzheimer's disease, with ASN51 advanced toward phase II clinical development.

Biomedical research on protein aggregation

Research on O-GlcNAc modification, toxic aggregates of tau and alpha-synuclein, and biomarkers related to drug development.

Outbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub

Asceneuron SA

About the company

Products & services

Looking for direct email addresses and phone numbers?

Asceneuron SA

About the company

Products & services

Looking for direct email addresses and phone numbers?

Mentions & media

No knowledge articles yet

Asceneuron SA in comparison

Industry comparisons are coming soon

Similar companies